ATC Group: N02BA15 Carbasalate calcium

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of N02BA15 in the ATC hierarchy

Level Code Title
1 N Nervous system
2 N02 Analgesics
3 N02B Other analgesics and antipyretics
4 N02BA Salicylic acid and derivatives
5 N02BA15 Carbasalate calcium

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
ORAL - Oral 3.6 g

Active ingredients in N02BA15

Active Ingredient Description
Carbasalate calcium

Carbasalate calcium is a complex of calcium acetyl salicylic acid and urea. It is a thrombocyte aggregation inhibitor. The antithrombotic effect is due to the irreversible acetylating of the enzyme cyclo-oxygenase in the thrombocyte, through which the formation of the prostaglandin thromboxane A2 is inhibited.

Medicines in this ATC group

Austria (AT)

Netherlands (NL)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.